Abstract: Orally administrable pharmaceutical compositions comprising an incretin or analog or derivative thereof are presented that allow for extended control of blood glucose. Formulations presented herein comprise a self-emulsifying drug delivery system (SEDDS). Advantageously such formulations afford protection from the proteolytic conditions in the upper gastrointestinal tract while allowing for effective drug release and absorption in the lower gastrointestinal tract.

Abstract: A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Such retro-Michael resistant composition is generally achieved by conformational modification of the albumin, resulting in stereoselective coupling of the linker to the albumin.